Video

Dr. Liao on Outcomes With Ivosidenib in Advanced Cholangiocarcinoma

Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.

Chih-Yi Liao, MD, assistant professor of medicine, University of Chicago Department of Medicine, discusses outcomes reported with ivosidenib (Tibsovo) in patients with advanced cholangiocarcinoma.

In the phase 3 ClarIDHy trial (NCT02989857), the agent was examined vs placebo in patients with IDH1-mutant, advanced cholangiocarcinoma. The primary end point of the trial was progression-free survival (PFS), which was met, according to Liao. Ivosidenib resulted in a PFS of 2.7 months vs 1.4 months with placebo in this population, Liao says. Although this may not seem numerically significant, it translates a 63% reduction in the risk of progression or death, Liao notes.

In terms of overall survival (OS), the median OS in patients who received treatment with ivosidenib was 10.3 months vs 7.5 months in those who were given placebo, Liao adds. Despite the numeric improvement, this was not found to be statistically significant, Liao concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP
Matthew Lawrence Inra, MD, thoracic surgeon, Lenox Hill Hospital, Northwell Health
Tony S. K. Mok, BMSc, MD, FASCO, Li Shu Fan Medical Foundation Endowed Professor, chairman, Department of Clinical Oncology, Chinese University of Hong Kong
Tanios Bekaii-Saab, MD, FACP